The Beijing Longitudinal Disability Survey in Community Elderly
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age65+
SponsorXuanwu Hospital, Beijing
About this trial
The goal of this observational study is to establish the prospective cohort of the Beijing Longitudinal Disability Survey in Community Elderly (BLINDSCE) to explore the high-risk factors and preventive interventions for disability and cognitive impairment among community-dwelling adults aged 65 years and over. The main question it aims to answer is:
* What are the high-risk factors able to predict the incidence and advance of disability and cognitive impairment in community-dwelling adults aged 65 years and over? * What are the categories of function and cognitive performance trajectory in community-dwelling adults aged 65 years and over?
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Community-dwelling adults aged 65 years or older who reside in Beijing.
Participants who sign an institutionally approved informed consent.
Disqualifiers
Participants with severe mental disorders and serious medical conditions preventing study investigation
Participants undergoing long-term professional treatment for physical function and cognitive functioning, such as hospitalization or rehabilitation.
Trial population
Community residents aged 65 years or older in Beijing
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Disability from the individual's perspective
Disability is assessed using the 12-item World Health Organization's Disability Assessment Schedule 2.0 (WHODAS 2.0). The WHODAS 2.0 is a patient-reported disability measure, comprising six life domains involving cognition, mobility, self-care, interpersonal relationships, life activities, and participation. The total score of 12-item WHODAS 2.0 categorizes disability from no disability (score 0) to complete disability (score 48).
Time frame
An average of 1 to 2 years2
Disability from the medical's perspective
Disability is assessed using the basic activities of daily living (BADL) scale, the Katz Index scale. The minimum value is 0 , and the maximum value is 6. The higher the score, the better the outcome.
Time frame
An average of 1 to 2 years3
Disability from the medical's perspective
Disability is assessed using the instrumental activities of daily living (IADL) scale, the Lawton and Brody IADL scale. The minimum value is 0, and the maximum value is 8. The higher the score, the better the outcome.
Time frame
An average of 1 to 2 yearsSecondary outcomes
1
Cognitive impairment
The cognitive impairment is assessed by the Mini-Mental State Examination (MMSE). The minimum value is 0, and the maximum value is 30. The higher the score, the better the outcome.
Time frame
An average of 1 to 2 years2
Cognitive impairment
The cognitive impairment is assessed by the Montreal Cognitive Assessment-Basic (MoCA-B). The minimum value is 0, and the maximum value is 30. The higher the score, the better the outcome.
Time frame
An average of 1 to 2 years3
Subjective cognitive decline
Subjective cognitive decline is assessed by the subjective cognitive decline questionnaire-9 items (SCD9). The minimum value of SCD9 is 0, and the maximum value is 9, the higher the score, the worse the outcome.
Time frame
An average of 1 to 2 years4
Intrinsic capacity
Intrinsic capacity is the composite of physical and mental abilities that an individual can draw upon. It comprises locomotor, sensory (hearing and vision), vitality, psychological, and cognition domains. The intrinsic capacity composite score is used to assess intrinsic capacity. The intrinsic capacity composite score ranges from 0 to 100, and the higher the score, the better the outcome.
Time frame
An average of 1 to 2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Xuanwu Hospital, Beijing
Lead sponsor
Beijing Municipal Health Commission
Collaborator
Source ClinicalTrials.gov